Chronotolerance of experimental radioimmunotherapy: Clearance, toxicity, and maximal tolerated dose of 131I-anti-carcinoembryonic antigen (CEA) IgG as a function of time of day of dosing in a murine model

European Journal of Cancer

Volumn 35, Issue 5, 1999, Pages 815-824

  Blumenthal, R D ^a   Reising, A ^a   Lew, W ^a   Dunn, R ^a   Ying, Z ^b   Goldenberg, D M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

CEA; Cell cycle; Chronobiology; Marrow; Neutropenia; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IODINE 131; PROPIDIUM IODIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHRONOBIOLOGY; CHRONOTHERAPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG TOLERABILITY; DRUG TOLERANCE; GRANULOCYTOPENIA; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; TREATMENT PLANNING; TUMOR XENOGRAFT;

ANIMALS; BONE MARROW CELLS; CARCINOEMBRYONIC ANTIGEN; CELL CYCLE; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOGLOBULIN G; IODINE RADIOISOTOPES; MALE; MICE; MICE, INBRED BALB C; RADIOIMMUNOTHERAPY; TIME FACTORS;

EID: 0033000154     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00432-8     Document Type: Article

References (33)

1. Smaaland R., Laerum O.D., Abrahamsen J.F. Circadian cell kinetics in humans. Aspects related to cancer chemotherapy. In Vivo. 9:1995;529-537.
2. Focan C. Marker rhythms for cancer chronotherapy. From laboratory animals to human beings. In Vivo. 9:1995;283-298.
3. Bjarnason G.A. Clinical chronotolerance to anticancer drugs: relevance for dose-intensity. In Vivo. 9:1995;557-564.
4. Levi F. Chronopharmacology and chronotherapy of cancers. Path. Biol. 44:1996;631-644.
5. Halberg E., Cornelissen G., Halberg F. Optimization of the chronotherapeutic index in the experimental animal laboratory. In Vivo. 6:1992;371-385.
6. Hrushesky W., Bjarnason G. Circadian cancer therapy. J. Clin. Oncol. 11:1993;1403-1417.
7. Vriesendorp H.M., Quadri S.M., Andersson B.S., Dicke K.A. Hematologic side effects of radiolabeled immunoglobulin therapy. Exp. Hematol. 24:1996;1183-1190.
8. Blumenthal R.D., Sharkey R.M., Haywood L., Behr T., Goldenberg D.M. Application of cytokine intervention for improved radio-antibody dose delivery. Int. J. Cancer. 72:1997;166-173.
9. Press O.W., Apelbaum F.R., Martin P., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. Engl. J. Med. 329:1993;1219-1224.
10. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329:1993;459-465.
11. Blumenthal R.D., Sharkey R.M., Goldenberg D.M. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression [see comments]. J. Natl. Cancer Inst. 84:1992;399-407.
12. Blumenthal R.D., Sharkey R.M., Forman D., Wong G., Hess J., Goldenberg D.M. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation. Exp. Hematol. 23:1995;1088-1097.
13. Morton B.A., Beatty B.G., Mison A.P., Wanek P.M., Beatty J.D. Role of bone marrow transplantation in 90Y antibody therapy of colon cancer xenografts in nude mice. Cancer Res. 50:1990;1008s-1010s.
14. Alisauskas R.M., Goldenberg D.M., Sharkey R.M., Blumenthal R.D. Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice. Int. J. Cancer. 70:1997;323-329.
15. Blumenthal R.D., . Sharkey R.M., Kashi R., Natale A.M., Goldenberg D.M. Influence of animal host and tumor implantation site on radio-antibody uptake in the GW-39 human colonic cancer xenograft. Int. J. Cancer. 44:1989;1041-1047.
16. Sharkey R.M., Juweid M., ShevitzH J., et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res. 55:1995;5935-5945.
17. Sharkey R.M., Blumenthal R.D., Haywod L., Forman D., Wong G., Goldenberg D., et al. Radioimmunotherapy using iodine-131, ytrium-90, or rhenium-188-labeled IgG and fragments in nude mice bearing well established or micrometastatic colonic tumors. Int. J. Cancer. 72:1997;477-485.
18. Nelson W., Tong Y., Lee J., Halberg F. Methods for cosinor rhythmometry. Chronobiologica. 6:1979;866-892.
19. Swoyer J., Haue E., Sackett-Lundeen L. Circadian reference values for hematologic parameters in several strains of mice. Prog. Clin. Biol. Res. 227A:1987;281-296.
20. Blumenthal R.D., Sharkey R.M., Forman D., Wong G., Goldenberg D.M. Cytokine intervention permits dose escalation of radioantibody. An analysis of myelostimulation by bolus versus continuous infusion of IL-1/GM-CSF. Cancer. 73:1994;1083-1092.
21. Reinberg A. Circadian rhythm in the sensitivity of target systems to drugs: an underestimated phenomenon. Bull. Acad. Natl. Med. 180:1996;533-543.
22. Belanger P. Circadian rhythms in hepatic biotransformation of drugs. Pathol. Biol. 44:1996;564-570.
23. Haus E. Biologic rhythms in hematology. Pathol. Biol. 44:1996;618-630.
24. Fernandes G., Halberg Y., Yunis E., Good G. Diurnal rhythmic plaque-forming cell response of spleens from mice immunized with SRBC. J. Immunol. 117:1976;962-969.
25. Loubaris N., Cros G., Serrano J., Boucard M. Diurnal and circadian variation of the carrageenin inflamatory effect in rat. Life Sci. 32:1983;1349-1356.
26. Young M., Matthews J., Kanabrocki E., Sothern R., Roitman-Johnson B., Scheving L. Circadian rhythmometry of serum interleukin-2, interleukin-10, tumor necrosis factor alpha, and granulocyte-macrophage colony stimulating factor. Chronobiol. Int. 12:1995;19-27.
27. Hayashi O., Kikuchi M. The effects of light-dark cycle on humoral and cell-mediated immune responses of mice. Chronobiologia. 9:1982;291-300.
28. Gudewill S., Pollmacher T., Vedder H., Schreiber W., Fassbender K., Holsboer F. Nocturnal plasma levels of cytokines in healthy men. Eur. Arch. Psychiatry Clin. Neurosci. 242:1992;53-56.
29. Pierpoint B., Le Bousse-Kerdiles C., Clay D., et al. In vitro chronopharmacology of recombinant mouse IL-3, mouse GM-CSF, and human G-CSF on murine myeloid progenitor cells. Exptl. Hematol. 23:1995;362-368.
30. Blumenthal RD, Sharkey RM, Goldenberg DM. Overcoming Dose-limiting, Radioantibody-induced Myelotoxicity. Boca Raton, CRC Press, 1995.
31. Behr T.M., Sharkey R.M., Juweid M.E., et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 55:1995;3825-3834.
32. Abo T., Kawate T., Itoh K., Kumagai K. Studies on the bioperiodicity of the immune response. 1. Circadian rhythms of human T, B, and K cell traffic in the peripheral blood. J. Immunol. 126:1981;1360-1363.
33. Smaaland R., Sothern R., Lote K., Sandberg S., Aakvaag A., Laerum O.D. Circadian phase relationships between peripheral blood variables and bone marrow proliferative activity in clinical health. In Vivo. 9:1995;379-390.